Bio-Techne Corporation (TECH) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $72.68 (-0.04%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 12, 2025 | Justin Bowers | Deutsche Bank | $72.00 | -0.9% |
| Sep 2, 2025 | Conor McNamara | RBC Capital | $73.00 | +0.4% |
| Oct 31, 2024 | Catherine Schulte | Robert W. Baird | $84.00 | +15.6% |
| Oct 30, 2024 | Paul Knight | KeyBanc | $80.00 | +10.1% |
| Aug 16, 2024 | Sung Ji Nam | Scotiabank | $83.00 | +14.2% |
| May 5, 2022 | Paul Knight | KeyBanc | $125.00 | +72.0% |
| May 6, 2021 | Patrick B Donnelly | Citigroup | $106.25 | +46.2% |
Top Analysts Covering TECH
TECH vs Sector & Market
| Metric | TECH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.80 | 2.25 | 2.41 |
| Analyst Count | 10 | 8 | 19 |
| Target Upside | -9.5% | +153002.0% | +21.5% |
| P/E Ratio | 142.51 | 3.34 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $308M | $314M | $320M | 7 |
| 2027-03-31 | $332M | $340M | $346M | 4 |
| 2027-06-30 | $342M | $349M | $355M | 6 |
| 2027-09-30 | $309M | $316M | $322M | 4 |
| 2027-12-31 | $328M | $335M | $341M | 7 |
| 2028-03-31 | $351M | $359M | $365M | 3 |
| 2028-06-30 | $367M | $375M | $382M | 5 |
| 2029-06-30 | $1.51B | $1.53B | $1.55B | 2 |
| 2030-06-30 | $1.69B | $1.71B | $1.73B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.49 | $0.51 | $0.52 | 6 |
| 2027-03-31 | $0.58 | $0.60 | $0.61 | 3 |
| 2027-06-30 | $0.61 | $0.62 | $0.64 | 5 |
| 2027-09-30 | $0.50 | $0.52 | $0.53 | 3 |
| 2027-12-31 | $0.58 | $0.59 | $0.61 | 6 |
| 2028-03-31 | $0.66 | $0.68 | $0.70 | 4 |
| 2028-06-30 | $0.66 | $0.68 | $0.70 | 6 |
| 2029-06-30 | $2.98 | $3.03 | $3.08 | 1 |
| 2030-06-30 | $3.10 | $3.15 | $3.20 | 1 |
Frequently Asked Questions
What is the analyst consensus for TECH?
The consensus among 10 analysts covering Bio-Techne Corporation (TECH) is Hold with an average price target of $65.78.
What is the highest price target for TECH?
The highest price target for TECH is $125.00, set by Paul Knight at KeyBanc on 2022-05-05.
What is the lowest price target for TECH?
The lowest price target for TECH is $72.00, set by Justin Bowers at Deutsche Bank on 2025-12-12.
How many analysts cover TECH?
10 analysts have issued ratings for Bio-Techne Corporation in the past 12 months.
Is TECH a buy or sell right now?
Based on 10 analyst ratings, TECH has a consensus rating of Hold (2.80/5) with a -9.5% upside to the consensus target of $65.78.
What are the earnings estimates for TECH?
Analysts estimate TECH will report EPS of $0.51 for the period ending 2026-12-31, with revenue estimated at $314M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.